The Day In Review: MGI PHARMA, INC. Sells Ex-US Dacogen Rights

Published: Jul 06, 2006

July 6, 2006 -- MGI Pharma out-licensed the ex-US rights for Dacogen, its treatment for myelodysplastic syndrome, to Cilag GmbH; SuperGen will receive half of the $10 million upfront payment from the MGI-Cilag agreement; King will assume full marketing responsibility for its ACE inhibitor, Altace, from Wyeth; Alnylam conflated two RNAi agreements with Merck into one with potential milestones of $120 million; MedImmune received FDA permission to use reverse genetics technology to produce flu vaccines; ISTA Pharma filed for approval of T-Pred, a treatment for eye inflammation and infection; Abbott signed an siRNA deal with Dharmacon; and Elan licensed its NanoCrystal technology to Abbott Labs. The Centient Biotech 200™ added on 27 points, closing at 3679.65, a gain of .74%. More details...

Back to news